1. Home
  2. NTCT vs GLUE Comparison

NTCT vs GLUE Comparison

Compare NTCT & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NetScout Systems Inc.

NTCT

NetScout Systems Inc.

SELL

Current Price

$39.64

Market Cap

2.0B

Sector

Technology

ML Signal

SELL

Logo Monte Rosa Therapeutics Inc.

GLUE

Monte Rosa Therapeutics Inc.

HOLD

Current Price

$18.16

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTCT
GLUE
Founded
1984
2019
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
1999
2021

Fundamental Metrics

Financial Performance
Metric
NTCT
GLUE
Price
$39.64
$18.16
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$31.00
$32.00
AVG Volume (30 Days)
665.7K
1.0M
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
125.39
N/A
EPS
1.30
N/A
Revenue
$891,820,000.00
$123,672,000.00
Revenue This Year
$6.02
N/A
Revenue Next Year
$2.55
$2.45
P/E Ratio
$30.52
$72.42
Revenue Growth
N/A
63.54
52 Week Low
$20.40
$4.12
52 Week High
$43.80
$25.77

Technical Indicators

Market Signals
Indicator
NTCT
GLUE
Relative Strength Index (RSI) 49.00 51.65
Support Level $38.38 $17.07
Resistance Level $40.92 $18.66
Average True Range (ATR) 1.44 1.20
MACD -0.48 0.10
Stochastic Oscillator 20.27 58.67

Price Performance

Historical Comparison
NTCT
GLUE

About NTCT NetScout Systems Inc.

NetScout Systems Inc is a provider of service assurance and cybersecurity solutions to enterprise and government networks. It bases its solutions on proprietary adaptive service intelligence technology, which helps customers monitor and identify performance issues and provides insight into network-based security threats. These solutions also deliver real-time and historical information, which provides insight to restore service and understand the quality of user experience. The company derives revenue from the sale of network management tools and security solutions. Its geographical regions include USA, which derives maximum revenue, Europe, Asia, and Rest of the World.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).

Share on Social Networks: